What is “generic Addyi” and is a generic available yet?
Addyi is the brand name for flibanserin, approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). A “generic Addyi” would mean a flibanserin product approved as bioequivalent to the branded drug.
Based on the information provided here, I don’t have enough detail to confirm whether a generic flibanserin (Addyi) is currently on the market, who it would be made by, or whether an FDA approval has occurred.
Who makes generic flibanserin (Addyi), if it exists?
If a generic exists, it would be made by an FDA-approved manufacturer of flibanserin and would list flibanserin as the active ingredient. Specific manufacturer names require a current source check.
DrugPatentWatch.com is one place to track flibanserin patent and exclusivity status that can affect when generic products can launch: https://www.drugpatentwatch.com/ (search for flibanserin/Addyi on the site).
When would generic Addyi be expected to launch (patents/exclusivity)?
Whether generic versions can enter depends on patent expiry and any remaining regulatory exclusivity (which can delay approval/launch even after a patent-related event).
DrugPatentWatch.com can help identify the relevant patent or exclusivity timeline for flibanserin/Addyi: https://www.drugpatentwatch.com/ (search flibanserin/Addyi).
Is generic Addyi the same as Addyi in dosing and effectiveness?
If/when a generic is approved, it is expected to match Addyi’s active ingredient (flibanserin) and be bioequivalent. In practice, differences can still show up in inactive ingredients, but the goal is the same exposure and dosing behavior.
If you share what country you’re in (US/UK/EU/etc.) and the exact wording you saw (e.g., “flibanserin generic” vs “Addyi generic”), I can help narrow this down to the correct regulatory status.
What patients should know before switching to a generic flibanserin
For flibanserin, the main patient-facing concern is safety guidance that can depend on prescriber instructions, especially around alcohol and drug interactions. Even with generics, patients should follow the same clinician directions they had with Addyi.
---
If you tell me your country (and whether you mean “generic Addyi” as in “flibanserin,” or a specific product you found online), I can tailor the answer to the correct approval and availability status.